Srdan Verstovsek

50PUBLICATIONS
140CO-AUTHORS
Cardiovascular medicine and haematology not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyGene and molecular therapyHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Aug 08, 2023
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.

Stephen T Oh, Ruben A Mesa, Claire N Harrison

|Aug 02, 2023
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.

Vikas Gupta, John Mascarenhas, Marina Kremyanskaya

|Jul 14, 2023
Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.

Helen T Chifotides, Srdan Verstovsek, Prithviraj Bose

|Apr 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.

Srdan Verstovsek, Ruben Mesa, Vikas Gupta

|Mar 17, 2023
Secondary erythrocytosis.

Rodrick Babakhanlou, Srdan Verstovsek, Naveen Pemmaraju

|Mar 07, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.

John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca

Pageof 9

Frequent Collaborators

15 joint publications

Prithviraj Bose

8 joint publications

Vikas K Gupta

7 joint publications

Jean-Jacques Kiladjian

7 joint publications

Ruben Mesa